News Search Results
Jun 13, 2024, 20:32 ET Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)
More news about: Innovent Biologics
Jun 12, 2024, 20:00 ET Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its TOPO1i anti-CLDN18.2
More news about: Innovent Biologics
Jun 12, 2024, 10:15 ET Veterinary Ophthalmology Equipment Market Hits $485M in 2024, Anticipates 7.5% CAGR to Reach $697M by 2029 | MarketsandMarkets™
COVID-19 pandemic, is propelling the demand for specialized veterinary services, notably in ophthalmology. This heightened awareness of pet health, including eye care, is fueling the growth of the veterinary ophthalmology equipment market. Market Restraints: High Cost of Veterinary Care The
More news about: MarketsandMarkets
Jun 12, 2024, 07:00 ET Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501
Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona and additional investors including Oxford Science Enterprises. Find out more
More news about: Beacon Therapeutics
Jun 11, 2024, 20:00 ET Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA)
More news about: Innovent Biologics
Jun 11, 2024, 10:46 ET Laser Technology Market to Be Worth $32.8 Billion by 2031 - Exclusive Report by Meticulous Research®
healthcare for procedures such as cosmetic surgeries, dermatology treatments, and ophthalmology; the rising integration of laser technology across manufacturing, automotive, and aerospace sectors to enhance processing capabilities and precision;
More news about: Meticulous Market Research Pvt. Ltd.
Jun 11, 2024, 07:45 ET QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors
several senior roles, most recently as vice president, business development, licensing M&A, and global head of neuroscience, rare disease, and ophthalmology partnering. There, he helped build a portfolio of medicines including Evrysdi® (risdiplam) for spinal muscular atrophy, Enspryng® (satralizumab-mwge)
More news about: QurAlis
Jun 10, 2024, 17:30 ET Vascular Endothelial Growth Factor (VEGF) Inhibitors Market size is set to grow by USD 11.66 billion from 2024-2028, High target affinity and specificity of VEGF inhibitors to boost the market growth, Technavio
Segment Covered Application (Oncology and Ophthalmology), Type (VEGF-A inhibitor, VEGF-B inhibitor, VEGF-C inhibitor, and VEGF-D inhibitor), and Geography (North America, Europe, Asia, and Rest of World
More news about: Technavio
Jun 10, 2024, 10:31 ET Medical Laser Market to Be Worth $17.3 Billion by 2031 - Exclusive Report by Meticulous Research®
laser devices, dye laser devices), fiber type (disposable laser fibers, reusable laser fibers)), application (device application (dermatology, ophthalmology, urology, dentistry, cardiology, gynecology, other device applications), fiber application (general surgeries, urology, dermatology, gynecology,
More news about: Meticulous Market Research Pvt. Ltd.
Jun 06, 2024, 07:00 ET Avulux Welcomes John A. Moran Eye Center To Its Family Of Providers
The John A. Moran Eye Center at the University of Utah is the largest ophthalmology clinical care and research facility in the Mountain West, with more than 60 faculty members and 10 satellite clinics. It is also where Avulux technology
More news about: Avulux
Jun 05, 2024, 06:45 ET Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Jun 04, 2024, 11:30 ET AMSURG and Palomar Health Form Strategic Surgery Center Partnership
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. With a focus on strategic growth and innovation, AMSURG is committed to transforming the future of ambulatory surgery center care
More news about: AMSURG
Jun 04, 2024, 09:00 ET HelpMeSee Welcomes Two Directors to Its Fast-Growing Cataract VR Simulation Training Programs
residents and fellows at Tufts University School of Medicine. Further, Dr. Fynn-Thompson has participated in global ophthalmology efforts in Ghana. With her firsthand experience in clinical and surgical decision-making, she will bring valuable
More news about: HelpMeSee, Inc.
Jun 04, 2024, 06:14 ET Bioimplants Market to Reach $364.8 Billion, Globally, by 2035 at 8.8% CAGR: Allied Market Research
Bioimplants Market by Type (Cardiovascular bioimplants, Dental bioimplants, Orthopedic bioimplants, Spinal bioimplants, Ophthalmology bioimplants, Other bioimplants), and End User (Hospitals, Speciality Clinics, Ambulatory Surgical Centers): Global Opportunity Analysis and Industry
More news about: Allied Market Research
Jun 03, 2024, 09:00 ET Covenant High Plains Surgery Center earns ACS Surgical Quality Partner designation from American College of Surgeons
well as advanced surgical treatment options in bariatrics, ENT, general surgery, GI, gynecology, interventional pain, neuro & spine surgery, ophthalmology, orthopedics, maxillofacial, plastic & reconstructive surgery, podiatry, and urology to patients from Texas,
More news about: Covenant High Plains Surgery Center
Jun 02, 2024, 21:41 ET Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, announced that the clinical data of a randomized controlled Phase 1b study evaluating IBI310
More news about: Innovent Biologics
Jun 02, 2024, 21:30 ET Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, delivered two oral presentations of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (R&D code: IBI389) for
More news about: Innovent Biologics
Jun 02, 2024, 01:13 ET Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating
More news about: Innovent Biologics
Jun 01, 2024, 20:00 ET Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented Phase 1 clinical data of IBI343 (TOPOi anti-CLDN18.2 ADC) for the treatment of advanced pancreatic ductal adenocarcinoma
More news about: Innovent Biologics
Jun 01, 2024, 20:00 ET Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating
More news about: Innovent Biologics
Jun 01, 2024, 20:00 ET Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, presented the Phase 1 clinical data of its first-in-class PD-1/IL-2α bispecific antibody fusion protein (R&D
More news about: Innovent Biologics
May 31, 2024, 03:00 ET SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
that is very debilitating in daily life and could lead to corneal transplant or enucleation of the eye, if untreated. We have been innovating in ophthalmology for almost 90 years and AKANTIOR® represents a significant milestone as well as a proof of our commitment to address unmet medical needs
More news about: SIFI S.p.A.
May 31, 2024, 03:00 ET SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
that is very debilitating in daily life and could lead to corneal transplant or enucleation of the eye, if untreated. We have been innovating in ophthalmology for almost 90 years and AKANTIOR® represents a significant milestone as well as a proof of our commitment to address unmet medical needs
More news about: SIFI S.p.A.
May 31, 2024, 03:00 ET SIFI erhält positives CHMP-Gutachten für AKANTIOR® (Polihexanid 0,08 %) bei Acanthamoeba-Keratitis
John Dart (Moorfields Eye Hospital und University College of London, Institute of Ophthalmology), Hauptprüfer der Phase-3-Studie. AKANTIOR® wird mit einer Polihexanid-Polymerkette von optimaler Länge hergestellt, die ein
More news about: SIFI S.p.A.
May 30, 2024, 14:56 ET InnoVoyce Receives FDA 510(k) Clearance for VYLO™ 455nm Blue Light Laser System
and efficacy make it suitable for use in general surgery, gastroenterology, gynecology, head and neck/otorhinolaryngology (ENT), neurosurgery, ophthalmology, plastic surgery, spinal surgery, thoracic surgery, and urology. This broad range of applications positions the VYLO system as a transformative
More news about: InnoVoyce